Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci

Autor: Patsopoulos NA, Esposito F, Reischl J, Lehr S, Bauer D, Heubach J, Sandbrink R, Pohl C, Edan G, Kappos L, Miller D, Montalbán X, Polman CH, Freedman MS, Hartung HP, Arnason BGW, COMI , GIANCARLO, Cook S, FILIPPI , MASSIMO, Goodin DS, Jeffery D, O'Connor P, Ebers GC, Langdon D, Reder AT, Traboulsee A, Zipp F, Schimrigk J, Hillert J, Bahlo M, Booth DR, BroadleyS, Brown MA, Browning BL, Browning SR, Butzkueven H, Carroll WM, Chapman C, Foote SJ, Griffiths L, Kermode AG, Kilpatrick TJ, Lechner Scott J, Marriott M, Mason D, Moscato P, Heard RN, Pender MP, Perreau VM, Perera D, Rubio JP, Scott RJ, Slee M, Stankovich J, Stewart GJ, Taylor BV, Tubridy N, Willoughby E, Wiley J, Matthews P, Boneschi F, Compston A, Haines J, Hauser SL, McCauley J, Ivinson A, Oksenberg JR, Pericak Vance M, Sawcer SJ, De Jager PL, Hafler DA, de Bakker PIW, the BSP MS Genetics working group, the steering committees of studies evaluating IFNb 1b, a. CCR1 antagonist, ANZgene Consortium, GeneMSA, International Multiple Sclerosis Genetics Consortium

Publikováno v: Annals of Neurology, 70(6), 897-912. John Wiley and Sons Inc.
Patsopoulos, N A, Bakker, P I W & Polman, C H 2011, ' Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci ', Annals of Neurology, vol. 70, no. 6, pp. 897-912 . https://doi.org/10.1002/ana.22609

OBJECTIVE: To perform a 1-stage meta-analysis of genome-wide association studies (GWAS) of multiple sclerosis (MS) susceptibility and to explore functional consequences of new susceptibility loci. METHODS: We synthesized 7 MS GWAS. Each data set was

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ef8585134ddd788a2ca78fc05301762
https://doi.org/10.1002/ana.22609

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis

Autor: Petkau, AJ, White, RA, Ebers, GC, Reder, AT, Sibley, WA, Lublin, FD, Paty, DW, Duquette, P, Girard, M, Despault, L, DuBois, R, Knobler, RL, Kelley, L, Francis, GS, Lapierre, Y, Antel, J, Freedman, M, Hum, S, Greenstein, JI, Mishra, B, Muldoon, J, Whitaker, JN, Evans, BK, Layton, B, Laguna, J, Krikawa, J, Oger, JJ, Kastrukoff, LF, Moore, GRW, Hashimoto, SA, Morrison, W, Nelson, J, Goodin, DS, Massa, SM, Gutteridge, E, Arnason, BGW, Noronha, A, Martia, R, Rice, GPA, Lesaux, J, Johnson, KP, Panitch, HS, Bever, CT, Conway, K, Wallenberg, JC, Bedell, L, van den Noort, S, Weinshenker, B, Weiss, W, Reingold, S, Pachner, A, Taylor, W

Publikováno v: Multiple Sclerosis. 10(2)

We have analysed dataon exacerbation rates, Expanded Disability Status Scale (EDSS) scores, and lesion burdens using the results of two neutralizing antibody (NAB) assays (CPE and MxA) from the pivotal relapsing i/remitting multiple sclerosis (MS) tr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e505dd19c0d8a072526a10982b50375
http://ora.ox.ac.uk/objects/uuid:1df9cc28-54d0-4335-9604-f62f8146dfc6

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: Experience during the first three years

Autor: Duquette, P, Girard, M, Dubois, R, Kobler, RL, Lublin, F, Kelley, L, Francis, GS, Freedman, M, Greenstein, JI, Mishra, B, DeLillio, N, Whitaker, J, Layton, B, Sibley, WA, Laguna, J, Krikawa, J, Paty, DW, Oger, JJ, Kastrukoff, LF, Morrison, W, Nelson, J, Goodin, D, Massa, SM, Gutteridge, E, Arnason, BGW, Noronha, A, Reder, AT, Martia, R, Ebers, GC, Rice, GPA, Lesaux, J, Johnson, KP, Panitch, HS, Bever, CT, Conway, K, Li, DKB, Tanton, EL, Zhao, GJ, Flak, B, Riddebough, A, Cover, K, Rhodes, B, Cook, A, Smith, K, Costley, L, Renneberg, S, Shaw, T, Genton, M, vandenNoort, S, Weinshenker, B, Weiss, W, Reingold, S, Taylor, W, Wallenberg, JC, Bedell, L, Lublin, FD

Publikováno v: NEUROLOGY. 47(4)

Evidence of diminution of therapeutic efficacy in 35% of interferon beta-1b (IFNB)-treated multiple sclerosis (MS) patients who developed neutralizing antibodies (NABs) led to extensive study of the effects of NABs on therapeutic benefits, side effec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ce92003e0f086f1376f1c63261eacbb
http://ora.ox.ac.uk/objects/uuid:c8aa5525-fea1-4ba7-ae06-babecb356304

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.